Munich - Delayed Quote EUR

Halozyme Therapeutics Inc (RV7.MU)

51.40

+0.08

+(0.16%)

As of 5:27:07 PM GMT+2. Market Open.

If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Simply Wall St. yesterday

HALO
Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market

Shares of biotech stock Halozyme found support at their 200-day line in a time where many stocks are below this level.

Investor's Business Daily 5 days ago

BMY

CELG-RT

HALO
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx has received U.S. Food and Drug Administration (FDA) approval of VYVGART® Hytrulo prefilled syringe for self-injection (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

PR Newswire 6 days ago

HALO
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission (EC) approval for an indication extension of DARZALEX® (daratumumab) subcutaneous (SC) co-formulated with ENHANZE® in the frontline setting. The approval is for daratumumab SC in combination with bortezomib, lenalidomide, and dexamethasone (daratumumab-VRd) for the treatment of adult patients with newly diagnosed multiple myeloma.1

PR Newswire 8 days ago

HALO
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 9 days ago

HALO
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, has received European Commission (EC) marketing authorization of the subcutaneous (SC) formulation of RYBREVANT® (amivantamab), in combination with LAZCLUZE® (lazertinib), for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mut

PR Newswire 10 days ago

HALO
Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Bristol Myers Squibb received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, recommending approval of a new Opdivo® (nivolumab) subcutaneous formulation developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20), across multiple previously approved adult solid tumors as monotherapy, monotherapy maintenance following

PR Newswire 17 days ago

HALO
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 20 days ago

HALO

^GSPC
Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 22 days ago

MYGN

HALO
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 24 days ago

HALO
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks 27 days ago

HALO
Halozyme Joins the $1 Billion Club

Halozyme Therapeutics, Inc. (HALO) shares up after passing $1 billion in revenue for first time, strong guidance.

FX Empire 27 days ago

HALO
Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue

Halozyme stock is in a consolidation pattern but its chart shows an alternate entry. The biotech name hit two milestones in 2024.

Investor's Business Daily last month

HALO
Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year?

Here is how Brookdale Senior Living (BKD) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

Zacks last month

BKDT

HALO
HALO vs. AMGN: Which Stock Is the Better Value Option?

HALO vs. AMGN: Which Stock Is the Better Value Option?

Zacks last month

AMGN

HALO
Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here’s Why

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. US stocks concluded a strong year with strong gains in Q4. In Q4, the portfolio’s performance was flat and narrowly trailed the Russell 2000® Growth Index. In 2024, the […]

Insider Monkey last month

HALO

^RUT
AutoZone Stock Can Hold Up Amid Tariffs, Analyst Says. Plus, Chewy, Chesapeake, and More.

Analysts also weigh in on Chesapeake Utilities, Halozyme Therapeutics, Sea Ltd., and Roper Technologies.

Barrons.com last month

AZO

CHWY

HALO
High Growth Tech Stocks To Watch In US March 2025

Over the last 7 days, the United States market has dropped 1.9%, yet it has risen by 14% over the past year, with earnings forecasted to grow by 14% annually. In this context of fluctuating short-term performance but promising long-term growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in a rapidly evolving sector.

Simply Wall St. last month

HALO

GERN

GERNW
Update: Market Chatter: Merck Faces Patent Dispute Over New Keytruda Version

(Updates to add the companies' comments in the fifth and sixth paragraphs) Merck (MRK) is facing

PREMIUM
MT Newswires last month

HALO
New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle

The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.

The Wall Street Journal last month

MRK

HALO

Performance Overview

Return	RV7.MU	S&P 500 (^GSPC)
YTD	+13.39%	-9.55%
1-Year	+42.74%	+5.92%
3-Year	+35.66%	+21.11%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Halozyme Therapeutics Inc (RV7.MU)

If EPS Growth Is Important To You, Halozyme Therapeutics (NASDAQ:HALO) Presents An Opportunity

Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report?

Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound?

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?

Halozyme Joins the $1 Billion Club

Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue

Is Brookdale Senior Living (BKD) Stock Outpacing Its Medical Peers This Year?

HALO vs. AMGN: Which Stock Is the Better Value Option?

Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Here’s Why

AutoZone Stock Can Hold Up Amid Tariffs, Analyst Says. Plus, Chewy, Chesapeake, and More.

High Growth Tech Stocks To Watch In US March 2025

Update: Market Chatter: Merck Faces Patent Dispute Over New Keytruda Version

New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle

Performance Overview